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1. Introduction 
Retroviral vectors have gained an increasing value in gene therapy because they stably deliver 
therapeutic genes to the host cell genome. These therapeutic genes are supposed to rectify 
consequences of inherited and acquired mutated genes in the host cell genome, or alter host 
cell function to cure diseases. In the following section we will discuss the biology and life cycle 
of retroviruses which starts with viral entry into the host cell, reverse transcription of viral 
RNA, nuclear import of the provirus, and finally integration of viral DNA into the cell host 
genome (Flint, Racaniello et al. 2004). Integration involves viral and host cellular proteins. 
Their role is discussed in the third and fourth sections of this chapter. Recently, the process of 
integration site selection (which is where the viral DNA integrates with the host cell DNA) has 
been quite understood throughout many in vitro and in vivo studies. The human genome 
project has enabled us to identify integration site preferences for retroviral vectors in human 
trials. The results of these human trials are reviewed in the fifth section of the chapter. Finally, 
the last section of the chapter will demonstrate the latest gene therapy trials attempts to control 
integration sites by manipulation of retrovirus genes and proteins. 
1.1 Retrovirus structure and life cycle 
Viruses are obligate parasites which depend on living cells to multiply. Their ability to 
deliver stable RNA and DNA into cells has determined their use in gene therapy. In 1983 
Mann et al. developed one of the first retroviral gene therapy vectors for delivery in vitro 
(Mann, Mulligan et al. 1983). This development was followed by many successfully gene 
therapy trials of retroviruses (Anderson, Blaese et al. 1990; Levine and Friedmann 1991; 
Blaese, Culver et al. 1993). Now, retrovirual vectors are implemented in nearly 22.2% of 
clinical trials (http://www.wiley.com//legacy/wileychi/genmed/clinical/[June 2010]).  
Retroviruses belong to the Retroviriade family. The retroviral particle consists of 2 copies of 
positive-single strand (+ss) RNA and viral proteins (reverse trascriptase, integrase, and 
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protease) which are all contained by nucleocapsid. The nucleocapsid complex is surrounded 
by a protein shell called capsid to form the viral core. A layer of matrix protein, which is 
formed outside the capsid, interacts with the envelope (env) which consists of lipid 
envelope derived from the host cell and viral envelope glycoproteins. Viral glycoproteins 
are made of two units: a transmembrane portion, which attaches the protein into the lipid 
bilayer, and a surface portion, which binds to the cellular receptor. 
The life cycle of the retrovirus consist of several steps. It begins with the binding of the viral 
envelope to cellular receptors, which enables fusion of the viral envelope with the cellular 
membrane. Consequently, the viral particle is uncoated, liberating the viral core into the cell 
cytoplasm. The viral DNA is reverse transcribed to DNA. Then, the viral DNA is 
transported to the nucleus where it is integrated into the host cell’s genome. From there, 
viral DNA is transcribed to RNA, some of which is translated to proteins. The viral RNA is 
packed in a viral particle along with viral proteins. Then, virion is produced when viral 
particles bud from the hosting cells (Escors and Breckpot).  
1.2 Integration 
The retroviral enzyme integrase (IN) plays a vital role in integration. It exists as a tetramer 
(dimer-of-dimers) inside the virion or the preintegration complex. IN facilitate viral DNA 
integration in vitro, even in the absence of other viral or cellular proteins (Coffin, Hughes et 
al. 1997; Flint, Racaniello et al. 2004). Integration is classified into two distinct steps. The first 
step called processing, where the IN removes two nucleotides from the 3’ ends of the viral 
DNA, the synthesis of which was produced by the viral enzyme reverse transcriptase 
(Coffin, Hughes et al. 1997; Flint, Racaniello et al. 2004). Then, when the viral preintegration 
complex is in the vicinity of targeted host DNA, IN catalyzes a coupled cleavage-joining 
reaction, where the 3’ ends of viral DNA are joined to host cell DNA, in the joining step 
(Coffin, Hughes et al. 1997; Flint, Racaniello et al. 2004). The intermediate product of the 
integration process is flanked by short single-stranded gaps in host cell DNA. After the 
integration reaction, postintegration repair takes place, in which the 5' ends of viral DNA are 
trimmed, the gaps filled, and ligated to host cell DNA. Lastly, the appropriate chromatin 
structure is reconstituted at the integration site. Postintegration repair does not require viral 
proteins, but instead depends on host cell DNA repair proteins (Daniel, Katz et al. 1999; Lau, 
Swinbank et al. 2005).  
In vitro experiments show that incubating IN with oligonucleotides as DNA substrate, and 
target DNA were sufficient to achieve integration of one end of the DNA substrate (Flint, 
Racaniello et al. 2004). However, in vivo, stable integration requires cellular proteins to be 
accomplished. These cellular proteins have invoked interest of their potential as cofactors of 
integration. Using a yeast two-hybrid screen, human immunodeficiency virus (HIV)-1 IN-
binding protein termed integrase interactor 1 (INI1) was identified (Kalpana, Marmon et al. 
1994). At the beginning, INI1 protein was found to boost integration efficiency when it was 
added to the integration reaction in vitro (Kalpana, Marmon et al. 1994). Also, small 
interfering RNA (siRNA) targeting INI1, demonstrated that knocking down INI1 was 
sufficient to significantly reduce HIV-1 replication (Ariumi, Serhan et al. 2006). However, 
another study showed that lacking INI1 protein did not affect integration reaction (Boese, 
Sommer et al. 2004). Now it is accepted that INI1 does not affect integration but it appears to 
be involved in other process of the retroviral life cycle (Ariumi, Serhan et al. 2006; 
Mahmoudi, Parra et al. 2006; Treand, du Chene et al. 2006). Another cellular non-histone 
chromatin protein called high-mobility group protein-1 (HMG-1) was found to enhance 
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integration in vitro (Aiyar, Hindmarsh et al. 1996). This enhancement was thought to be 
attributed to its DNA-bending ability (Aiyar, Hindmarsh et al. 1996; Flint, Racaniello et al. 
2004). HMG-I(Y), another related protein in the HMG family, was found in HIV-1 
preintegration complexes (Farnet and Bushman 1997). As with HMG-1, HMG-I(Y) and 
HMG-2 boost integration in in vitro (Aiyar, Hindmarsh et al. 1996; Farnet and Bushman 
1997; Hindmarsh, Ridky et al. 1999). Unfortunately, studies using HMG-I(Y) deficient cells 
did not elucidate the role of this protein in the integration reaction (Beitzel and Bushman 
2003). Thus the role of HMG proteins in integration remains unclear. Autointegration is the 
integration of the viral DNA into itself which will eventually abort the retroviral life cycle. 
An 89 amino acid protein, which was identified in murine leukemia virus (MLV) 
preintegration complexes, forbids autointegration of viral DNA, and was hence called the 
barrier-to-autointegration factor (BAF) (Lee and Craigie 1998). Also BAF was detected in 
HIV-1 preintegration complex to block autointegration (Lin and Engelman 2003). Finally, in 
2003, a yeast two-hybrid system resulted in the isolation of a new HIV-1 IN-binding protein, 
a previously identified cellular protein termed LEDGF/p75 (lens epithelium-derived growth 
factor) (Cherepanov, Devroe et al. 2004). In knockout mice experiments, LEDGF/p75 was 
found not to be a lens growth factor, actually, the knockout mice of the mouse LEDGF/p75 
homolog, PSIP1 (PC4 and SFRS1-interacting protein-1), had skeletal abnormalities, 
indicating that this protein is involved in bone development (Sutherland, Newton et al. 
2006). Furthermore, many studies demonstrate that LEDGF/p75 targeting with siRNA or 
LEDGF/p75 null cells, from the LEDGF/p75 null transgenic animals, showed that 
integration of HIV-1-based vectors is reduced 89–96% in the absence of LEDGF/p75 (Llano, 
Saenz et al. 2006; Shun, Raghavendra et al. 2007). Therefore, LEDGF/p75 appears to be 
essential for efficient integration of HIV-1. Meanwhile, numerous studies displayed that 
LEDGF/p75 does not bind to MLV IN nor is it essential for MLV integration (Llano, 
Vanegas et al. 2004; Busschots, Vercammen et al. 2005; Shun, Raghavendra et al. 2007). In 
addition to the LEDGF/p75 role in enhancing integration in in vitro, it has the ability to 
target HIV-1 and HIV-1-based vector integration sites (Ciuffi, Llano et al. 2005; Llano, 
Vanegas et al. 2006; Shun, Raghavendra et al. 2007). 
In summary, retroviral DNA integration is catalyzed by the viral protein integrase, but host 
cell proteins play a significant role in enhancing the efficiency of the reaction, and 
preventing autointegration. 
2. Integration site preferences of retroviruses and retroviral vectors 
While Integration of viral DNA can take place anywhere in the host cell genome and there is 
no strict host sequence for site selection, many studies showed that site selection is not a 
haphazard process (Schroder, Shinn et al. 2002; Wu, Li et al. 2003; Mitchell, Beitzel et al. 
2004). In vitro studies demonstrated that some DNA-binding proteins can prevent contact of 
IN to target DNA and subsequently block the integration reaction at their binding sites 
(Pryciak and Varmus 1992; Bushman 1994). On the contrary, bending or distortion of DNA 
seems to enhance integration (Pryciak, Muller et al. 1992; Pryciak and Varmus 1992; Katz 
and Skalka 1994; Pruss, Bushman et al. 1994; Pruss, Reeves et al. 1994). Furthermore, studies 
showed that DNA wrapping around nucleosomes promotes distortion of DNA and thus 
promotes integration in the nucleosomes-bound DNA (Pryciak, Sil et al. 1992; Pryciak and 
Varmus 1992; Pruss, Bushman et al. 1994). All of the previous studies show that there are 
certain integration site preferences in DNA substrate in in vitro models. However, it should 
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be considered that host DNA exists in a higher order chromatin structure, as the results of 
these in vitro studies may not translate to what really happens in the infected cell. To mimic 
the in vivo model, Taganov et al. used a 13-nucleosome extended array which includes 
binding sites for specific transcription factors and can be compacted into a higher-ordered 
structure using the histone H1 (Taganov, Cuesta et al. 2004).  They noticed that chromatin 
structure impacts the integration site selection of HIV-1 and avian sarcoma virus (ASV) IN 
proteins differentially. In particular, HIV-1 IN-mediated integration was reduced after 
compaction of the target DNA/chromatin structure, whereas ASV IN-mediated integration 
was more efficient after compaction (Taganov, Cuesta et al. 2004). These results reveal that a 
higher order chromatin structure is involved in integration site selection and variant 
retroviruses may exhibit differential selectivity of their integration. According to the 
International Human Genome Sequencing Consortium (IHGSC), in 2004, 25,000 genes had 
been identified in the human genome. In 1990, two studies indicated that retroviruses have a 
preference to integrate in the vicinity of transcriptionally active regions (Mooslehner, Karls 
et al. 1990; Scherdin, Rhodes et al. 1990). These studies were challenged by the relatively low 
number of identified transcription sites (Bushman, Lewinski et al. 2005). Also, due to 
incomplete human genome sequencing, the percentage of the genome containing these 
“favored” integration sites was not clear. Thus, after the IHGSC announcement, researchers 
were able to define accurate statistical analysis of integration sites. Large-scale studies on 
HIV-1 integration in human T cell lines revealed that roughly 70% of integration events 
occurred in genes (Schroder, Shinn et al. 2002; Bushman, Lewinski et al. 2005). Furthermore, 
the 11q13 chromosomal region was found to be a “hotspot” of integration. Also, Schroder et 
al. showed similar results when using pseudotyped HIV-1-based vectors (Schroder, Shinn et 
al. 2002). Many studies have revealed that many retroviruses and retroviral vectors like 
simian immunodeficiency virus, an SIV-based vector, HIV-2, and feline immunodeficiency 
virus (FIV) integration preferences resemble HIV-1 integration preferences (Hematti, Hong 
et al. 2004; Crise, Li et al. 2005; Kang, Moressi et al. 2006; MacNeil, Sankale et al. 2006). On 
the contrary, MLV and MLV-based vectors demonstrated diverse integration preferences 
compared with HIV-1 (Wu, Li et al. 2003; Mitchell, Beitzel et al. 2004; Lewinski, Yamashita et 
al. 2006). 20% of MLV integration occasions occur in the vicinity of the 5’ ends of 
transcription (Wu, Li et al. 2003), approximately 17% of MLV integration events take place 
in the vicinity of CpG islands (Mitchell, Beitzel et al. 2004), 11% of the integration sites were 
detected in the vicinity of DNase I-hypersensitive sites (Lewinski, Yamashita et al. 2006), 
and the remaining integration sites are scattered in a random manner (Wu, Li et al. 2003).  
Avian retroviruses and vectors show only a weak preference for integration around genes 
(about 40%) and no MLV-like preference for 5’ ends of transcription units (Mitchell, Beitzel 
et al. 2004; Narezkina, Taganov et al. 2004). Interestingly, high levels of transcription may 
even inhibit ASV integration in genes (Weidhaas, Angelichio et al. 2000; Maxfield, Fraize et 
al. 2005). These preferences are consistent with the above-described data from the in vitro 
system, which used nucleosomal arrays (Taganov, Cuesta et al. 2004). Interestingly, the 
human T-leukemia virus type 1 (HTLV-1) and mouse mammary tumor virus (MMTV), like 
avian retroviruses, do not specifically target genes and transcription start sites (Derse, Crise 
et al. 2007; Faschinger, Rouault et al. 2008).  
Lastly, it appears that there is a symmetric base preferences surrounding integration sites for 
integration of HIV-1, SIV, MLV, and avian sarcoma-leukosis viruses (Crise, Li et al. 2005; 
Holman and Coffin 2005). These weak consensus sequences are virus specific and possibly 
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reflect the influence of IN on integration site selection (Holman and Coffin 2005). This 
proposal is supported by the symmetry of the target site sequence, because IN likely 
functions as a tetramer (Coffin et al., 1997; Flint et al., 2004; Wu et al., 2005; and see above).  
In summary, the integration preferences described in this section are distinct for different 
group of retroviruses. The first group including HIV-1, HIV-2, SIV, and FIV, show a 
preferential integration into genes (Daniel and Smith 2008). While the second group, 
consisting of MLV and FV, integrate in 5' ends of transcription units and CpG islands. The 
last group consists of AVLS, HTLV-1, and MMTV (Daniel and Smith 2008). This group 
shows weak or even no preferences for gene or transcription start sites. Also, it appears that 
DNA sequence has a role in integration site selection. However, other factors (cellular 
cofactors and cellular structures) are likely to be the principal controllers of integration site 
selection.   
3. Mechanism of integration site selection 
As mentioned before, IN has a low specificity for binding to host cell DNA. So, it seems that 
host cell proteins participate in the integration process. Using the yeast two-hybrid system, 
Debyser and coworkers have identified a new HIV-1 IN-binding protein, termed 
LEDGF/p75 (Cherepanov, Maertens et al. 2003). LEDGF/p75 is required for efficient 
integration of HIV-1 DNA.  Also, LEDGF/p75 is a transcription factor and has a C-terminal 
IN-binding domain and N-terminal chromatin-binding domain (Cherepanov, Maertens et 
al. 2003; Cherepanov, Devroe et al. 2004; Vanegas, Llano et al. 2005; Llano, Vanegas et al. 
2006; Turlure, Maertens et al. 2006). Chromatin binding is mediated by PWWP and AT-hook 
motifs in the N-termianl domain of LEDGF/p75 (Llano, Vanegas et al. 2006; Turlure, 
Maertens et al. 2006). In addition, LEDGF/p75 was detected in association with 
preintegration complexes of HIV-1 and FIV in cultured cells (Llano, Vanegas et al. 2006). 
Moreover, LEDGF/p75 halts proteasomal degradation of ectopically expressed HIV-1 IN, 
therefore it might assist to the stability of preintegration complexes during infection 
(Maertens, Cherepanov et al. 2003; Llano, Vanegas et al. 2006). Also, LEDGF/p75 null cells 
showed that the residual integration sites in these cells no longer take place in active genes 
(Shun, Raghavendra et al. 2007). However, integration occurred preferentially near 
promoters and CpG islands (Shun, Raghavendra et al. 2007). The symmetric base 
preferences surrounding the integration site remained preserved (Holman and Coffin 2005). 
As a result, in the absence of LEDGF/p75, HIV-1 integration site preferences resemble those 
of MLV (Shun, Raghavendra et al. 2007). All these results strongly support the hypothesis 
that LEDGF/p75 targets HIV-1 (and other lentiviral) integration into active genes by 
tethering the IN protein to chromatin.  
Although LEDGF/p75 appears to be a major HIV-1 IN-binding cellular protein, other 
factors are likely involved in integration site selection by HIV-1 and HIV-1-based vectors. 
Analysis of robust number of integration sites demonstrated that preferred integration sites 
are found in the vicinity of certain computer-predicted epigenetic marks, such as histone H3 
K4 methylation, H4 acetylation, or H3 aceytlation  (Kalpana, Marmon et al. 1994). These 
results may suggest that the chromatin structure, including the histone code, may also affect 
integration site selection. However the decisive evidence that these marks play a role in 
integration site selection has yet to be revealed. Moreover, other factors which affect 
integration site selection have been identified. Knockdown of the T-cell lineage-specific 
chromatin organizer, SATB1 (special AT-rich sequence-binding protein-1), reduces HIV-1 
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integration in the vicinity of SATB1-binding sites (Kumar, Mehta et al. 2007). Consequently, 
SATB1 seems to be implicated in integration site selection by an unknown mechanism. 
Lastly, it has been shown that the cellular protein Ku80, which is present in the 
preintegration complex, directs integration to chromatin domains prone to silencing (Li, 
Olvera et al. 2001; Masson, Bury-Mone et al. 2007). In contrast to HIV-1, integration of MLV-
based and ASV-based vectors does not seem to be determined by LEDGF/p75 (Mitchell, 
Beitzel et al. 2004; Narezkina, Taganov et al. 2004). It is still unknown what controls ASV 
integration site selection. While in the case of MLV, a study using HIV chimeras with MLV 
genes demonstrated that MLV IN appears to be the major director for integration site 
selection (Lewinski, Yamashita et al. 2006). Furthermore, Gag-derived proteins play an 
auxiliary role in the integration selection process, as an HIV-1 chimera with MLV Gag 
demonstrated other site preferences different from both HIV and MLV (Lewinski, 
Yamashita et al. 2006). All the previous data support a different mechanism of integration 
site selection for MLV versus HIV.  
In conclusion, current data has promoted our understating of the retroviral site selection 
process and demonstrates a major role of host cell proteins in the process. Yet, the process is 
not entirely understood, and there will likely be new determinate members involved in the 
retroviral integration site selection process revealed in the near future.  
4. Integration site selection and gene therapy 
MLV and HIV-1 vectors are the two most widely used vectors in gene therapy. It was 
hypothesized that even if a retroviral vector integrates in the "wrong spot", it may not 
necessarily lead to the development of a tumor (Hahn and Weinberg 2002; Baum, Kustikova 
et al. 2006). However, this hypothesis was challenged when serious adverse effects emerged 
in gene therapy trials involving children to treat X-linked severe combined 
immunodeficiency (SCID-X1) (Hacein-Bey-Abina, Von Kalle et al. 2003; Alexander, Ali et al. 
2007; Bushman 2007; Deichmann, Hacein-Bey-Abina et al. 2007; Faschinger, Rouault et al. 
2008). In one these trials, which used an MLV-based vector, 4 out of 11 patients developed T 
cell leukemia. Moreover, in another SCID-X1 gene therapy trial, it has been reported that a 
patient, of 10 patients enrolled, developed leukemia (Alexander, Ali et al. 2007; 
Schwarzwaelder, Howe et al. 2007; Thrasher and Gaspar 2008). Using sequencing analysis, T 
cells from two of the patients in the first trial who developed leukemia, showed an insertion 
of the vector near (and subsequent activation of) Lin-1, IsI-1, Mec-3 (LIM) domain only-2 
(LMO2) protooncogene by the long terminal repeat (LTR) enhancer of the vector  (Hacein-
Bey-Abina, Von Kalle et al. 2003). Also, in the second trial, the vector insertion was in the 
vicinity of the LMO2 protooncogene (Thrasher and Gaspar 2008).  These striking data 
demonstrate that vector integration at a dangerous spot of the human genome could lead to 
cancer development. It is also true that there could be other unknown factors that 
contributed to the leukemia development. Proposed factors that may have been involved 
are expression of the transgenes and chromosomal rearrangement (Hacein-Bey-Abina, Von 
Kalle et al. 2003; Pike-Overzet, de Ridder et al. 2006; Thrasher, Gaspar et al. 2006; Woods, 
Bottero et al. 2006). A follow-up analysis of the patients of these gene therapy trials 
exhibited a nonrandom distribution of integration sites in vivo (Deichmann, Hacein-Bey-
Abina et al. 2007; Schwarzwaelder, Howe et al. 2007). Integration of vectors occurred 
preferentially near the 5' ends of genes and associated CpG islands, which is consistent with 
the data obtained with MLV in in vitro studies (Bushman 2007; Deichmann, Hacein-Bey-
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Abina et al. 2007; Schwarzwaelder, Howe et al. 2007). Comparison of integration sites, in 
transduced-cells before and after infusion into patients, showed that vector integration 
manipulates cell growth, survival and proliferation in vivo (Deichmann, Hacein-Bey-Abina 
et al. 2007; Schwarzwaelder, Howe et al. 2007). Similarly, clonal evolution was noticed in a 
gene therapy trial using ADA-SCID. However, in this trial, no adverse effects were related 
with vector integration site (Aiuti, Cassani et al. 2007). In similar trials, vector insertion 
caused a deregulation of gene expression without any development of cancer (Ott, Schmidt 
et al. 2006; Recchia, Bonini et al. 2006). Likewise, animal gene therapy model results were 
similar to results obtained in human gene therapy trials (Li, Dullmann et al. 2002; Hematti, 
Hong et al. 2004; Modlich, Kustikova et al. 2005; Baum, Kustikova et al. 2006; Montini, 
Cesana et al. 2006). Moreover, Kaiser described in his article the first successful gene therapy 
for Beta-thalassemia disease using an HIV vector to correct β-globin coding gene (Kaiser 
2009). The infused cells with corrected genes were highly proliferating due to 
overexpression of mutated HMGA2. The follow-up of the patient did not show any serious 
adverse effects, still the elevation  of HMGA2 seems to be a caveat.  
In conclusion, integration of a retroviral vector into the human genome contributed to the 
development of leukemia both in animal models and human patients.  Nevertheless, these 
insertions may not be directly involved in cancer development, few patients of gene therapy 
trials developed malignancies (Hacein-Bey-Abina, Von Kalle et al. 2003; Dave, Jenkins et al. 
2004). These cases emphasize the need for further improvements of retroviral vector designs 
to obtain vectors with low preferences for “wrong spots” to increase the safety margin in 
gene therapy applications.  
5. Retargeting integration 
The hypothetical need for integration targeting was realized even prior to the adverse 
events described above. Thus, attempts to target integration were made in the last decade of 
the 20th century. These attempts involved attaching a specific DNA binding domain 
(binding to a known DNA sequence) to the retroviral integrase protein.  It had been shown 
that these fusion proteins target integration in vitro (“testube”), however, when these 
proteins were introduced into a vector particle, they either failed to perform integration or 
did not target it efficiently to predicted sites ((Goulaouic and Chow 1996)). Following the 
discovery of LEDGF/p75, it has been hypothesized that it is possible to retarget integration 
using a modified LEDGF/p75 protein. Thus, the Daniel laboratory created a fusion protein, 
in which the LEDGF/p75 chromatin binding domain was replaced by the chromatin 
binding domain of the heterochromatin protein 1a (HP-1a, (Silvers, Smith et al.)). HP-1a 
binds to the trimethylated lysine 9 of the histone H3, which is a hallmark of 
heterochromatin. It should be noted that cellular chromatin consists of euchromatin, 
containing most genes, and heterochromatin, which contains mainly repetitive sequences 
and relatively few genes. Thus, integration into heterochromatin should be “safer” than 
integration into euchromatin and genes.  This fusion protein, when transfected into cells 
prior to infection with a HIV-1 vector, indeed reduced integration events occurring in genes. 
Other labs, following a similar strategy, demonstrated that further reduction in genes can be 
achieved by knocking down the endogenous LEDGF/p75 (Ferris, Wu et al. 2010; Gijsbers, 
Ronen et al. 2010). It should be noted that the knockdown did not result in reduced 
integration efficiency, because the novel fusion proteins efficiently replaced LEDGF/p75 
function. These results thus pave the way to retargeting integration, and reducing the safety 
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risk in gene therapy trials. However, caveats remain. One disadvantage of these methods is 
that targeting requires two vectors, one to deliver the fusion LEDGF/p75-based protein, and 
one to deliver the therapeutic genes. In addition, a significant percentage of integrations still 
occurred in genes. One possible approach to address the first weakness is to introduce the 
targeting protein directly into a vector particle. It is possible that the second disadvantage 
can be removed by using chromatin binding domains that show more specificity for 
heterochromatin than that of HP-1a. These approaches are currently being explored. We 
hope they ultimately result in self-targeting HIV-1 vectors that can carry negligible risk of 
adverse events in gene therapy trials.  
6. References 
Aiuti, A., B. Cassani, et al. (2007). "Multilineage hematopoietic reconstitution without clonal 
selection in ADA-SCID patients treated with stem cell gene therapy." J Clin Invest 
117(8): 2233-40. 
Aiyar, A., P. Hindmarsh, et al. (1996). "Concerted integration of linear retroviral DNA by the 
avian sarcoma virus integrase in vitro: dependence on both long terminal repeat 
termini." J Virol 70(6): 3571-80. 
Alexander, B. L., R. R. Ali, et al. (2007). "Progress and prospects: gene therapy clinical trials 
(part 1)." Gene Ther 14(20): 1439-47. 
Anderson, W. F., R. M. Blaese, et al. (1990). "The ADA human gene therapy clinical protocol: 
Points to Consider response with clinical protocol, July 6, 1990." Hum Gene Ther 
1(3): 331-62. 
Ariumi, Y., F. Serhan, et al. (2006). "The integrase interactor 1 (INI1) proteins facilitate Tat-
mediated human immunodeficiency virus type 1 transcription." Retrovirology 3: 
47. 
Baum, C., O. Kustikova, et al. (2006). "Mutagenesis and oncogenesis by chromosomal 
insertion of gene transfer vectors." Hum Gene Ther 17(3): 253-63. 
Beitzel, B. and F. Bushman (2003). "Construction and analysis of cells lacking the HMGA 
gene family." Nucleic Acids Res 31(17): 5025-32. 
Blaese, R. M., K. W. Culver, et al. (1993). "Treatment of severe combined immunodeficiency 
disease (SCID) due to adenosine deaminase deficiency with CD34+ selected 
autologous peripheral blood cells transduced with a human ADA gene. 
Amendment to clinical research project, Project 90-C-195, January 10, 1992." Hum 
Gene Ther 4(4): 521-7. 
Boese, A., P. Sommer, et al. (2004). "Ini1/hSNF5 is dispensable for retrovirus-induced 
cytoplasmic accumulation of PML and does not interfere with integration." FEBS 
Lett 578(3): 291-6. 
Bushman, F., M. Lewinski, et al. (2005). "Genome-wide analysis of retroviral DNA 
integration." Nat Rev Microbiol 3(11): 848-58. 
Bushman, F. D. (1994). "Tethering human immunodeficiency virus 1 integrase to a DNA site 
directs integration to nearby sequences." Proc Natl Acad Sci U S A 91(20): 9233-7. 
Bushman, F. D. (2007). "Retroviral integration and human gene therapy." J Clin Invest 
117(8): 2083-6. 
Busschots, K., J. Vercammen, et al. (2005). "The interaction of LEDGF/p75 with integrase is 
lentivirus-specific and promotes DNA binding." J Biol Chem 280(18): 17841-7. 
www.intechopen.com
 
Integration Targeting and Safety in Gene Therapy 
 
11 
Cherepanov, P., E. Devroe, et al. (2004). "Identification of an evolutionarily conserved 
domain in human lens epithelium-derived growth factor/transcriptional co-
activator p75 (LEDGF/p75) that binds HIV-1 integrase." J Biol Chem 279(47): 48883-
92. 
Cherepanov, P., G. Maertens, et al. (2003). "HIV-1 integrase forms stable tetramers and 
associates with LEDGF/p75 protein in human cells." J Biol Chem 278(1): 372-81. 
Ciuffi, A., M. Llano, et al. (2005). "A role for LEDGF/p75 in targeting HIV DNA integration." 
Nat Med 11(12): 1287-9. 
Coffin, J. M., S. H. Hughes, et al. (1997). Retroviruses. Plainview, NY, Cold Spring Harbor 
Laboratory Press. 
Crise, B., Y. Li, et al. (2005). "Simian immunodeficiency virus integration preference is 
similar to that of human immunodeficiency virus type 1." J Virol 79(19): 12199-204. 
Daniel, R., R. A. Katz, et al. (1999). "A role for DNA-PK in retroviral DNA integration." 
Science 284(5414): 644-7. 
Daniel, R. and J. A. Smith (2008). "Integration site selection by retroviral vectors: molecular 
mechanism and clinical consequences." Hum Gene Ther 19(6): 557-68. 
Dave, U. P., N. A. Jenkins, et al. (2004). "Gene therapy insertional mutagenesis insights." 
Science 303(5656): 333. 
Deichmann, A., S. Hacein-Bey-Abina, et al. (2007). "Vector integration is nonrandom and 
clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy." J Clin 
Invest 117(8): 2225-32. 
Derse, D., B. Crise, et al. (2007). "Human T-cell leukemia virus type 1 integration target sites 
in the human genome: comparison with those of other retroviruses." J Virol 81(12): 
6731-41. 
Escors, D. and K. Breckpot "Lentiviral vectors in gene therapy: their current status and 
future potential." Arch Immunol Ther Exp (Warsz) 58(2): 107-19. 
Farnet, C. M. and F. D. Bushman (1997). "HIV-1 cDNA integration: requirement of HMG 
I(Y) protein for function of preintegration complexes in vitro." Cell 88(4): 483-92. 
Faschinger, A., F. Rouault, et al. (2008). "Mouse mammary tumor virus integration site 
selection in human and mouse genomes." J Virol 82(3): 1360-7. 
Ferris, A. L., X. Wu, et al. (2010). "Lens epithelium-derived growth factor fusion proteins 
redirect HIV-1 DNA integration." Proc Natl Acad Sci U S A 107(7): 3135-40. 
Flint, S. E., V. R. Racaniello, et al. (2004). Principles of Virology. Washington, D.C., ASM 
Press. 
Gijsbers, R., K. Ronen, et al. (2010). "LEDGF hybrids efficiently retarget lentiviral integration 
into heterochromatin." Mol Ther 18(3): 552-60. 
Goulaouic, H. and S. A. Chow (1996). "Directed integration of viral DNA mediated by fusion 
proteins consisting of human immunodeficiency virus type 1 integrase and 
Escherichia coli LexA protein." J Virol 70(1): 37-46. 
Hacein-Bey-Abina, S., C. Von Kalle, et al. (2003). "LMO2-associated clonal T cell 
proliferation in two patients after gene therapy for SCID-X1." Science 302(5644): 
415-9. 
Hahn, W. C. and R. A. Weinberg (2002). "Rules for making human tumor cells." N Engl J 
Med 347(20): 1593-603. 
Hematti, P., B. K. Hong, et al. (2004). "Distinct genomic integration of MLV and SIV vectors 
in primate hematopoietic stem and progenitor cells." PLoS Biol 2(12): e423. 
www.intechopen.com
  
Viral Gene Therapy 
 
12
Hindmarsh, P., T. Ridky, et al. (1999). "HMG protein family members stimulate human 
immunodeficiency virus type 1 and avian sarcoma virus concerted DNA 
integration in vitro." J Virol 73(4): 2994-3003. 
Holman, A. G. and J. M. Coffin (2005). "Symmetrical base preferences surrounding HIV-1, 
avian sarcoma/leukosis virus, and murine leukemia virus integration sites." Proc 
Natl Acad Sci U S A 102(17): 6103-7. 
Kaiser, J. (2009). "Gene therapy. Beta-thalassemia treatment succeeds, with a caveat." Science 
326(5959): 1468-9. 
Kalpana, G. V., S. Marmon, et al. (1994). "Binding and stimulation of HIV-1 integrase by a 
human homolog of yeast transcription factor SNF5." Science 266(5193): 2002-6. 
Kang, Y., C. J. Moressi, et al. (2006). "Integration site choice of a feline immunodeficiency 
virus vector." J Virol 80(17): 8820-3. 
Katz, R. A. and A. M. Skalka (1994). "The retroviral enzymes." Annu Rev Biochem 63: 133-73. 
Kumar, P. P., S. Mehta, et al. (2007). "SATB1-binding sequences and Alu-like motifs define a 
unique chromatin context in the vicinity of human immunodeficiency virus type 1 
integration sites." J Virol 81(11): 5617-27. 
Lau, A., K. M. Swinbank, et al. (2005). "Suppression of HIV-1 infection by a small molecule 
inhibitor of the ATM kinase." Nat Cell Biol 7(5): 493-500. 
Lee, M. S. and R. Craigie (1998). "A previously unidentified host protein protects retroviral 
DNA from autointegration." Proc Natl Acad Sci U S A 95(4): 1528-33. 
Levine, F. and T. Friedmann (1991). "Gene therapy techniques." Curr Opin Biotechnol 2(6): 
840-4. 
Lewinski, M. K., M. Yamashita, et al. (2006). "Retroviral DNA integration: viral and cellular 
determinants of target-site selection." PLoS Pathog 2(6): e60. 
Li, L., J. M. Olvera, et al. (2001). "Role of the non-homologous DNA end joining pathway in 
the early steps of retroviral infection." Embo J 20(12): 3272-81. 
Li, Z., J. Dullmann, et al. (2002). "Murine leukemia induced by retroviral gene marking." 
Science 296(5567): 497. 
Lin, C. W. and A. Engelman (2003). "The barrier-to-autointegration factor is a component of 
functional human immunodeficiency virus type 1 preintegration complexes." J 
Virol 77(8): 5030-6. 
Llano, M., D. T. Saenz, et al. (2006). "An essential role for LEDGF/p75 in HIV integration." 
Science 314(5798): 461-4. 
Llano, M., M. Vanegas, et al. (2004). "LEDGF/p75 determines cellular trafficking of diverse 
lentiviral but not murine oncoretroviral integrase proteins and is a component of 
functional lentiviral preintegration complexes." J Virol 78(17): 9524-37. 
Llano, M., M. Vanegas, et al. (2006). "Identification and characterization of the chromatin-
binding domains of the HIV-1 integrase interactor LEDGF/p75." J Mol Biol 360(4): 
760-73. 
MacNeil, A., J. L. Sankale, et al. (2006). "Genomic sites of human immunodeficiency virus 
type 2 (HIV-2) integration: similarities to HIV-1 in vitro and possible differences in 
vivo." J Virol 80(15): 7316-21. 
Maertens, G., P. Cherepanov, et al. (2003). "LEDGF/p75 is essential for nuclear and 




Integration Targeting and Safety in Gene Therapy 
 
13 
Mahmoudi, T., M. Parra, et al. (2006). "The SWI/SNF chromatin-remodeling complex is a 
cofactor for Tat transactivation of the HIV promoter." J Biol Chem 281(29): 19960-8. 
Mann, R., R. C. Mulligan, et al. (1983). "Construction of a retrovirus packaging mutant and 
its use to produce helper-free defective retrovirus." Cell 33(1): 153-9. 
Masson, C., S. Bury-Mone, et al. (2007). "Ku80 participates in the targeting of retroviral 
transgenes to the chromatin of CHO cells." J Virol 81(15): 7924-32. 
Maxfield, L. F., C. D. Fraize, et al. (2005). "Relationship between retroviral DNA-integration-
site selection and host cell transcription." Proc Natl Acad Sci U S A 102(5): 1436-41. 
Mitchell, R. S., B. F. Beitzel, et al. (2004). "Retroviral DNA integration: ASLV, HIV, and MLV 
show distinct target site preferences." PLoS Biol 2(8): E234. 
Modlich, U., O. S. Kustikova, et al. (2005). "Leukemias following retroviral transfer of 
multidrug resistance 1 (MDR1) are driven by combinatorial insertional 
mutagenesis." Blood 105(11): 4235-46. 
Montini, E., D. Cesana, et al. (2006). "Hematopoietic stem cell gene transfer in a tumor-prone 
mouse model uncovers low genotoxicity of lentiviral vector integration." Nat 
Biotechnol 24(6): 687-96. 
Mooslehner, K., U. Karls, et al. (1990). "Retroviral integration sites in transgenic Mov mice 
frequently map in the vicinity of transcribed DNA regions." J Virol 64(6): 3056-8. 
Narezkina, A., K. D. Taganov, et al. (2004). "Genome-wide analyses of avian sarcoma virus 
integration sites." J Virol 78(21): 11656-63. 
Ott, M. G., M. Schmidt, et al. (2006). "Correction of X-linked chronic granulomatous disease 
by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or 
SETBP1." Nat Med 12(4): 401-9. 
Pike-Overzet, K., D. de Ridder, et al. (2006). "Gene therapy: is IL2RG oncogenic in T-cell 
development?" Nature 443(7109): E5; discussion E6-7. 
Pruss, D., F. D. Bushman, et al. (1994). "Human immunodeficiency virus integrase directs 
integration to sites of severe DNA distortion within the nucleosome core." Proc 
Natl Acad Sci U S A 91(13): 5913-7. 
Pruss, D., R. Reeves, et al. (1994). "The influence of DNA and nucleosome structure on 
integration events directed by HIV integrase." J Biol Chem 269(40): 25031-41. 
Pryciak, P. M., H. P. Muller, et al. (1992). "Simian virus 40 minichromosomes as targets for 
retroviral integration in vivo." Proc Natl Acad Sci U S A 89(19): 9237-41. 
Pryciak, P. M., A. Sil, et al. (1992). "Retroviral integration into minichromosomes in vitro." 
EMBO J 11(1): 291-303. 
Pryciak, P. M. and H. E. Varmus (1992). "Nucleosomes, DNA-binding proteins, and DNA 
sequence modulate retroviral integration target site selection." Cell 69(5): 769-80. 
Recchia, A., C. Bonini, et al. (2006). "Retroviral vector integration deregulates gene 
expression but has no consequence on the biology and function of transplanted T 
cells." Proc Natl Acad Sci U S A 103(5): 1457-62. 
Scherdin, U., K. Rhodes, et al. (1990). "Transcriptionally active genome regions are preferred 
targets for retrovirus integration." J Virol 64(2): 907-12. 
Schroder, A. R., P. Shinn, et al. (2002). "HIV-1 integration in the human genome favors active 
genes and local hotspots." Cell 110(4): 521-9. 
Schwarzwaelder, K., S. J. Howe, et al. (2007). "Gammaretrovirus-mediated correction of 
SCID-X1 is associated with skewed vector integration site distribution in vivo." J 
Clin Invest 117(8): 2241-9. 
www.intechopen.com
  
Viral Gene Therapy 
 
14
Shun, M. C., N. K. Raghavendra, et al. (2007). "LEDGF/p75 functions downstream from 
preintegration complex formation to effect gene-specific HIV-1 integration." Genes 
Dev 21(14): 1767-78. 
Silvers, R. M., J. A. Smith, et al. "Modification of integration site preferences of an HIV-1-
based vector by expression of a novel synthetic protein." Hum Gene Ther 21(3): 
337-49. 
Sutherland, H. G., K. Newton, et al. (2006). "Disruption of Ledgf/Psip1 results in perinatal 
mortality and homeotic skeletal transformations." Mol Cell Biol 26(19): 7201-10. 
Taganov, K. D., I. Cuesta, et al. (2004). "Integrase-specific enhancement and suppression of 
retroviral DNA integration by compacted chromatin structure in vitro." J Virol 
78(11): 5848-55. 
Thrasher, A. J. and H. B. Gaspar (2008) "Severe adverse event in clinical trial of gene therapy 
for X-SCID."  Volume,  DOI:  
Thrasher, A. J., H. B. Gaspar, et al. (2006). "Gene therapy: X-SCID transgene 
leukaemogenicity." Nature 443(7109): E5-6; discussion E6-7. 
Treand, C., I. du Chene, et al. (2006). "Requirement for SWI/SNF chromatin-remodeling 
complex in Tat-mediated activation of the HIV-1 promoter." Embo J 25(8): 1690-9. 
Turlure, F., G. Maertens, et al. (2006). "A tripartite DNA-binding element, comprised of the 
nuclear localization signal and two AT-hook motifs, mediates the association of 
LEDGF/p75 with chromatin in vivo." Nucleic Acids Res 34(5): 1653-65. 
Vanegas, M., M. Llano, et al. (2005). "Identification of the LEDGF/p75 HIV-1 integrase-
interaction domain and NLS reveals NLS-independent chromatin tethering." J Cell 
Sci 118(Pt 8): 1733-43. 
Weidhaas, J. B., E. L. Angelichio, et al. (2000). "Relationship between retroviral DNA 
integration and gene expression." J Virol 74(18): 8382-9. 
Woods, N. B., V. Bottero, et al. (2006). "Gene therapy: therapeutic gene causing lymphoma." 
Nature 440(7088): 1123. 
Wu, X., Y. Li, et al. (2003). "Transcription start regions in the human genome are favored 
targets for MLV integration." Science 300(5626): 1749-51. 
www.intechopen.com
Viral Gene Therapy
Edited by Dr. Ke Xu
ISBN 978-953-307-539-6
Hard cover, 450 pages
Publisher InTech
Published online 20, July, 2011
Published in print edition July, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
The development of technologies that allow targeting of specific cells has progressed substantially in recent
years for several types of vectors, particularly viral vectors, which have been used in 70% of gene therapy
clinical trials. Particular viruses have been selected as gene delivery vehicles because of their capacities to
carry foreign genes and their ability to efficiently deliver these genes associated with efficient gene expression.
This book is designed to present the most recent advances in viral gene therapy
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Ahmed F. Salem, Johanna Smith, Michael Lisanti and Rene Daniel (2011). Retroviral Vectors in Gene
Therapy: Mechanism of Integration, Successes in Gene Therapy Trials, Emerging Problems and Potential
Solutions, Viral Gene Therapy, Dr. Ke Xu (Ed.), ISBN: 978-953-307-539-6, InTech, Available from:
http://www.intechopen.com/books/viral-gene-therapy/retroviral-vectors-in-gene-therapy-mechanism-of-
integration-successes-in-gene-therapy-trials-emergin
© 2011 The Author(s). Licensee IntechOpen. This chapter is distributed
under the terms of the Creative Commons Attribution-NonCommercial-
ShareAlike-3.0 License, which permits use, distribution and reproduction for
non-commercial purposes, provided the original is properly cited and
derivative works building on this content are distributed under the same
license.
